Trial Profile

Phase I/IB Trial of Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TTI 101 (Primary)
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

08 Jul 2025 Status changed from suspended to recruiting.
04 Jun 2025 Planned number of patients changed from 35 to 18.
27 Dec 2024 Status changed from recruiting to suspended. ( Interim analysis )

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com